

Cell stress modulates the function of splicing regulatory protein RBM4 in translation control

Jung-Chun Lin*[†], Min Hsu*, and Woan-Yuh Tarn*[‡]

*Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan; and [†]Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan

Communicated by Joan A. Steitz, Yale University, New Haven, CT, December 19, 2006 (received for review November 8, 2006)

RNA-binding motif protein 4 (RBM4) plays a regulatory role in alternative splicing of precursor mRNA. We show here that cell stress such as arsenite exposure induces phosphorylation of RBM4 at serine 309 and also drives its cytoplasmic accumulation and targeting to stress granule via the MKK_{3/6}-p38 signaling pathway. Accordingly, RBM4 suppresses cap-dependent translation in a cis-element-dependent manner. However, RBM4 concomitantly activates internal ribosome entry site (IRES)-mediated translation likely by promoting the association of translation initiation factor eIF4A with IRES-containing mRNAs. Overexpression of RBM4 therefore mimics the effect of cell stress-induced signaling on translation initiation control. Whereas arsenite treatment promotes RBM4 loading onto IRES mRNAs and enhances RBM4–eIF4A interactions, a nonphosphorylatable mutant of RBM4 was unresponsive to arsenite stress and failed to activate IRES-mediated translation. Thus, our results uncover a previously unrecognized paradigm for the RNA-binding protein RBM4 in its phosphorylation-modulated dual action as a suppressor of cap-dependent and enhancer of IRES-mediated translation in response to stress signals.

cell stress | eIF4A | internal ribosome entry site | phosphorylation | splicing factor

Posttranscriptional control of eukaryotic gene expression comprises several levels of regulation such as processing, export, turnover, localization, and translation of mRNAs (1). Each regulation step involves various combinations of RNA-binding proteins that form dynamic messenger ribonucleoproteins with the transcript. These messenger ribonucleoproteins may individually play specific roles in mRNA metabolism by forming distinct regulatory complexes (2). Some of them continuously shuttle between the nucleus and cytoplasm and may thus participate in multiple steps of mRNA metabolism in different subcellular compartments. For example, nuclear precursor mRNA splicing factors serine/arginine-rich (SR) proteins were recently implicated in several postsplicing activities including mRNA export, quality control, and translation (1, 3–5).

Cellular signaling pathways may relocate messenger ribonucleoproteins and thereby modulate their function. For example, environmental stimuli such as osmotic shock induce phosphorylation and cytoplasmic accumulation of heterogeneous nuclear ribonucleoprotein (hnRNP) A1 via the MAPK pathway and hence alter its activity in splicing regulation (6, 7). Activation of the ERK signaling pathway can drive cytoplasmic accumulation of hnRNP K; blockade of this pathway attenuates the ability of hnRNP K to inhibit translation (8).

The cellular response to environmental stress immediately leads to global repression of protein synthesis and aggregation of stalled translation complexes in cytoplasmic foci termed stress granules (SGs) (9, 10). However, stress-induced attenuation of global translation is also accompanied by selective translation of mRNAs that possess internal ribosome entry sites (IRES) (11, 12). In particular, IRES-mediated translation promotes the expression of several stress-response genes, which either allows cell survival or conversely leads to cell death during stress (13–16). The efficiency of IRES-mediated initiation could be

differentially modulated by IRES trans-acting factors (ITAFs) (11, 14). At present, how ITAFs act in IRES-dependent initiation and how their activity is regulated by cellular signaling cascades still remain to be deciphered. Because at least $\approx 3\text{--}5\%$ of human genes are predicted to undergo IRES-mediated translation (15), it is important to understand more about the mechanisms underlying this process.

RNA-binding motif protein 4 (RBM4) is ubiquitously expressed with higher abundance in heart and muscle (17). RBM4 acts as a precursor mRNA splicing regulatory factor and can modulate cell type-specific exon selection of α -tropomyosin by binding to intronic CU-rich elements (18). It functionally antagonizes the activity of polypyrimidine tract-binding protein (PTB) by competing for overlapping cis-elements to determine α -tropomyosin exon selection. Moreover, RBM4 is a nucleocytoplasmic shuttling protein (17), but its cytoplasmic function was not determined.

Here we report that phosphorylation of RBM4 can be induced by cell stress, which accompanies its subcellular relocalization. More interestingly, RBM4 could suppress cap-dependent translation but, on the other hand, activate IRES-mediated translation under the control of cell stress signaling.

Results

Cell Stress Induces Phosphorylation and Cytoplasmic Accumulation of RBM4. We wondered whether RBM4 is a phosphoprotein and therefore tested this possibility by using ³²P to metabolically label the cells that were transiently expressing FLAG-tagged RBM4. Immunoprecipitated FLAG-RBM4 was radiolabeled, indicating its phosphorylation (Fig. 1B, WT). Because the sequence RDRS³⁰⁹P within the C-terminal domain of RBM4 (Fig. 1A) resembles the SR protein kinase (SRPK) phosphorylation site consensus (19), we tested whether serine 309 is a phosphoacceptor site. Alanine substitution of this serine residue in the RBM4 SA mutant largely abrogated ³²P incorporation, suggesting that Ser-309 is the major site of phosphorylation (Fig. 1B, SA). To investigate the biological relevance of RBM4 phosphorylation, we generated antibodies (anti-pS309) against an RBM4 peptide bearing phosphorylated Ser-309. Immunoblotting showed that anti-pS309 could recognize RBM4 that had been phosphorylated *in vitro* by purified recombinant SRPK1 (Fig. 1C). When phosphorylated RBM4 was further treated with

Author contributions: W.-Y.T. designed research; J.-C.L. and M.H. performed research; J.-C.L. and W.-Y.T. analyzed data; and W.-Y.T. wrote the paper.

The authors declare no conflict of interest.

Abbreviations: SR, serine/arginine-rich; hnRNP, heterogeneous nuclear ribonucleoprotein; SG, stress granule; IRES, internal ribosome entry site; ITAF, IRES trans-acting factors; EMCV, encephalomyocarditis virus; PTB, polypyrimidine tract-binding protein.

[†]To whom correspondence should be addressed at: Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road Section 2, Nankang, Taipei 115, Taiwan. E-mail: wvtarn@ibms.sinica.edu.tw.

This article contains supporting information online at www.pnas.org/cgi/content/full/0611015104/DC1.

© 2007 by The National Academy of Sciences of the USA




Fig. 1. Arsenite stress induces phosphorylation and subcellular relocation of RBM4. (A) The domain structure of RBM4. RRM and CCHC represent RNA recognition motif and zinc finger, respectively. (B) HeLa cells that transiently expressed the wild-type (WT) or SA mutant of FLAG-RBM4 were metabolically labeled with ^{32}P -orthophosphate. Anti-FLAG immunoprecipitates were analyzed by autoradiography and immunoblotting using anti-FLAG. (C) MBP-RBM4 was *in vitro* phosphorylated by recombinant SRPK1. The reaction was mock treated or treated with alkaline phosphatase (AP) followed by immunoblotting using anti-RBM4 and anti-pS309. (D) HEK 293 cells were treated with $0.5\ \mu\text{M}$ sodium arsenite (Ars) for 1 h. Immunoblotting of total cell lysate and subcellular fractions was performed using anti-pS309 and anti-RBM4. (E) HeLa cells were transiently transfected with the GFP-RBM4 expression vector (*Upper*) or cotransfected with vectors for expressing FLAG-RBM4 and HA-TIA-1 (*Lower*), followed by arsenite treatment as in D. (*Upper*) Fluorescence of GFP-RBM4 in mock cells and cells treated with arsenite (Ars #1 and Ars #2). (*Lower*) Double immunofluorescence using both anti-FLAG and anti-HA.

phosphatase, its immunoreactivity was lost, demonstrating the specificity of anti-pS309 (Fig. 1C).

We next asked whether RBM4 phosphorylation can be modulated upon changes in cell growth conditions or environments. Using anti-pS309, we found that phosphorylation of RBM4 was significantly enhanced when cells were exposed to $0.5\ \mu\text{M}$ sodium arsenite for 1 h (Fig. 1D, total). Arsenite stress-induced phosphorylation of RBM4 occurred primarily at Ser-309, because transiently expressed SA mutant remained unlabeled when cells were fed with ^{32}P (data not shown). We next examined the subcellular distribution of RBM4 under stress conditions. Fig. 1D shows that arsenite treatment increased RBM4 protein levels in the cytoplasm, with a concomitant decline of nuclear RBM4 (α -RBM4). Similar results were obtained using anti-pS309, indicating that phosphorylated RBM4 relocates from the nucleus to the cytoplasm upon arsenite treatment.

To verify arsenite-induced relocation of RBM4, RBM4 fusion to GFP was transiently expressed in HeLa cells. Like endogenous RBM4, GFP-RBM4 could be detected by anti-pS309 (data not shown) and localized primarily in the nucleus (Fig. 1E). Upon cell exposure to arsenite, GFP-RBM4 appeared in the cytoplasm (Fig. 1E, Ars #1). Notably, in $\approx 50\%$ of the transfectants, RBM4 showed evident signals in cytoplasmic foci (Ars #2). When coexpressed with TIA-1 (Fig. 1E) or PABP1 (data not shown), robust colocalization of RBM4 with these SG-




Fig. 2. Arsenite stress transduces signals to RBM4 via the MKK_{3/6}-p38 signaling pathway. (A *Upper*) HEK 293 cells were transfected with an empty vector or vector encoding wild-type (wt) or a dominant-negative (dn) mutant of p38 kinase. At 48 h posttransfection, arsenite (Ars) treatment was carried out. RBM4 in the cytoplasmic (cyto) and nuclear fractions (nucl) was detected using anti-RBM4; nucleolin was used as a loading control. (A *Lower*) HeLa cells were cotransfected with the GFP-RBM4 expression vector and a p38 kinase vector followed by arsenite (Ars) treatment. Values given are the percentage of the cells expressing cytoplasmic GFP-RBM4 in ≈ 100 positively transfected cells; average was obtained from three independent experiments. (B *Upper*) Constitutively active MKK_{3/6}-DD was transiently expressed in HEK 293 cells alone or together with the wild-type or dominant-negative mutant of p38 kinase. Cell fractionation and immunoblotting were performed as in A. (B *Lower*) Transfection of HeLa cells with the GFP-RBM4 vector alone or together with MAPK(s), and data quantitation were as in A.

associated proteins was observed. In conclusion, upon various stress treatments such as arsenite (this study) and heat shock (data not shown), RBM4 could become phosphorylated and translocate to the cytoplasm and SGs.

Cell Stress Targets RBM4 via the MKK_{3/6}-p38 Signaling Pathway.

We next examined cellular signaling pathways that are involved in arsenite-induced cytoplasmic accumulation of RBM4. Pretreatment of HeLa cells with the p38 MAPK inhibitor SB203580 could diminish cytoplasmic signals of GFP-RBM4 even under stress conditions [supporting information (SI) Fig. 7]. Accordingly, cell fractionation experiments showed that transient expression of a dominant-negative p38 mutant, which is defective in its kinase activity, prevented the arsenite-induced cytoplasmic increase of RBM4 (Fig. 2A *Upper*). Consistently, fluorescent images revealed that cytoplasmic GFP-RBM4 was barely detected when the mutant p38 kinase was coexpressed in arsenite-treated HeLa cells (Fig. 2A *Lower*).

When cells expressed both constitutively active MKK_{3/6}-DD and wild-type p38 kinases, the level of RBM4 in the cytoplasmic fraction was substantially increased (Fig. 2B *Upper*). Indeed, GFP-RBM4 became detectable in the cytoplasm of $\approx 30\%$ of the transfected cells upon overexpression of MKK_{3/6}-DD alone (Fig. 2B *Lower*). Coexpression of MKK_{3/6}-DD and wild-type p38 kinase allowed the majority of the cells showing GFP-RBM4 signals in the cytoplasm, albeit with fewer foci compared with arsenite treatment (Fig. 2B *Lower*). Nevertheless, the dominant-negative p38 kinase failed to enhance the effect of MKK_{3/6}-DD upon relocation of RBM4 to the cytoplasm (Fig. 2B *Lower*). Thus, activation of the MKK_{3/6}-p38 pathway could mimic the effect of arsenite-induced stress on driving cytoplasmic relo-

(30, 31). Therefore, our observation argues that RBM4 acts in conjunction with eIF4A on IRES-mediated translation initiation. Our data also revealed that arsenite stress induced RBM4 binding to cellular mRNAs encoding Bcl-2 and c-Myc. Although whether translation of these two mRNAs is mediated by authentic IRES is still being debated (23, 32), RBM4 may activate their expression either through IRES or via a not-yet-known mechanism but also involving eIF4A in response to cell stresses.

At present, how ITAFs modulate IRES-mediated translation remains at the periphery of our knowledge. Some ITAFs, such as La and PTB, may act as RNA chaperones to remodel IRES RNA conformation (16, 33). In addition, PTB can promote 48S complex assembly at the initiation codon of IRES (34). This report provides some clues to the mechanism of RBM4 in IRES-mediated translation initiation. We observe here that cell stress augmented the association of RBM4 with eIF4A and that overexpression of RBM4 promoted loading of eIF4A onto different IRES-containing mRNAs (Figs. 4 and 5). Thus, RBM4 participates in IRES-mediated translation control largely through the activity of eIF4A and perhaps in a cis-element-independent manner. To our knowledge, this is perhaps a previously unrecognized mechanism for an ITAF that activates IRES translation.

The question as to where IRES-mediated translation occurs is not directly addressed. Our results show that RBM4 bound to several IRES mRNAs and activated IRES translation as did eIF4A. Although RBM4 is colocalized with eIF4A in SGs, a part of these two proteins still remained in the cytoplasm under stress conditions (data not shown). SGs are thought to act as sites for stalled translation initiation (35). Yet, we observed that SG protein TIA-1 failed to bind any IRESs tested (data not shown). Thus, IRES translation may take place outside the SGs in the cytoplasm under stress conditions (Fig. 6B).

Materials and Methods

Stress Treatment. Cells were cultured at a confluency of ≈ 70 –80% and treated with 0.5 μM sodium arsenite for 1 h before harvest.

In Vivo Translation Assay. The cap-dependent translation assay was performed by cotransfection of *Renilla* luciferase reporter pRL-

SV40 (or derivatives thereof) as well as firefly luciferase control vector pGL3-control (Promega, Madison, WI) with the FLAG-RBM4 expression vector into HEK 293 cells. For the IRES translation assay, the dicistronic pFR-Luc vector [a kind gift of Y. Chern (Academia Sinica)] containing EMCV IRES nucleotides 363–859 (Fig. 4A; similar to GW34 in 4) was used as a reporter. HEK 293 cells were cotransfected with pFR-Luc and an effector expression vector for 48 h and were then lysed in Passive Lysis Buffer (Promega). The reporter transcripts were examined by RT-PCR; no spurious splicing products (5) were detected (data not shown). Firefly and *Renilla* luciferase activities were measured by using the Dual-Luciferase Reporter Assay system (Promega) on a luminometer (Berthold, Nashua, NH). The data were collected from at least three independent experiments.

In Vitro Translation Assay. Plasmid pRL-SV40 (and derivatives thereof) and pFR-Luc were linearized and used as templates for *in vitro* transcription; these transcripts were diguanosine-capped but had no poly(A) tail. *In vitro*-transcribed RNA was recovered by precipitation with 7 M LiCl and quantified by UV spectrophotometry. The 25- μl *in vitro* translation reaction contained 10 ng of *in vitro*-transcribed RNA, 0.5–50 pmol of His-tagged mouse RBM4 (3), 25 μM amino acids, and 12.5 μl of reticulocyte lysate (Promega). The reaction was incubated at 30°C for 2 h, and 10% of the mixture was subjected to the luciferase assay as described above. Each reaction was independently performed at least three times.

Plasmids, Recombinant Proteins, Antibodies, Phosphorylation, Immunofluorescence, Immunoprecipitation, and RT-PCR. Complete details are provided in *SI Materials and Methods*.

We are grateful to J. Cáceres, W. Chang, Y. Chern, and N. Kedersha for providing plasmids, and to Nahum Sonenberg (McGill University, Montreal, QC, Canada) and Joan Steitz (Yale University) for helpful comments on the manuscript. We thank members of our laboratory, G. Gopal, I.-W. Hsu, H.-W. Kuo, and P.-J. Peng, for helpful discussions and technical assistance. We thank T. C. Taylor for editing the manuscript. This work was supported by Grant NHRI-EX94-9426NI from the National Health Research Institutes of Taiwan.

- Moore MJ (2005) *Science* 309:1514–1518.
- Singh R, Valcárcel J (2005) *Nat Struct Mol Biol* 12:645–653.
- Zhang Z, Krainer AR (2004) *Mol Cell* 16:597–607.
- Huang Y, Steitz JA (2005) *Mol Cell* 17:613–615.
- Sanford JR, Gray NK, Beckmann K, Cáceres JF (2004) *Genes Dev* 18:755–768.
- van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat J, Cáceres JF (2000) *J Cell Biol* 149:307–316.
- Allemand E, Guil S, Myers M, Moscat J, Cáceres JF, Krainer AR (2005) *Proc Natl Acad Sci USA* 102:3605–3610.
- Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW, Ronai Z (2001) *Nat Cell Biol* 3:325–330.
- Gebauer F, Hentze MW (2004) *Nat Rev Mol Cell Biol* 5:827–835.
- Kedersha NL, Anderson P (2002) *Biochem Soc Trans* 30(Pt 6):963–969.
- Hellen CU, Sarnow P (2001) *Genes Dev* 15:1593–1612.
- Holcik M, Sonenberg N (2005) *Nat Rev Mol Cell Biol* 6:318–327.
- Holcik M, Sonenberg N, Korneluk RG (2000) *Trends Genet* 16:469–473.
- Stoneley M, Willis AE (2004) *Oncogene* 23:3200–3207.
- Komar AA, Hatzoglou M (2005) *J Biol Chem* 280:23425–23428.
- Spriggs KA, Bushell M, Mitchell SA, Willis AE (2005) *Cell Death Differ* 12:585–591.
- Lai MC, Kuo HW, Chang WC, Tarn WY (2003) *EMBO J* 22:1359–1369.
- Lin JC, Tarn WY (2005) *Mol Cell Biol* 25:10111–10121.
- Nolen B, Yun CY, Wong CF, McCammon JA, Fu XD, Ghosh G (2001) *Nat Struct Biol* 8:176–183.
- Thoma C, Bergamini G, Galy B, Hundsdoerfer P, Hentze MW (2004) *Mol Cell* 15:925–935.
- Kaminski A, Jackson RJ (1998) *RNA* 4:626–638.
- Kolupaeva VG, Lomakin IB, Pestova TV, Hellen CU (2003) *Mol Cell Biol* 23:687–698.
- Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE (2004) *J Biol Chem* 279:29066–29074.
- Sayed M, Kim SO, Salh BS, Olaf-Georg I, Pelech SL (2000) *J Biol Chem* 275:16569–16573.
- Kamachi M, Le TM, Kim SJ, Geiger ME, Anderson P, Utz PJ (2002) *J Exp Med* 196:1213–1225.
- Mylonis I, Giannakouros T (2003) *Biochem Biophys Res Commun* 301:650–656.
- Liu X, Mayeda A, Tao M, Zheng ZM (2003) *J Virol* 77:2105–2115.
- Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadran L, Sanford JR, Muschietti JP, Kornblihtt AR, Srebrow A, et al. (2005) *Nat Struct Mol Biol* 12:1037–1044.
- Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, Sonenberg N (2005) *Mol Cell Biol* 25:10556–10565.
- Belsham GJ, Jackson RJ (2000) in *Translation Control of Gene Expression*, eds Sonenberg N, Hershey JWB, Mathews M (Cold Spring Harbor Lab Press, Woodbury, NY), pp 869–900.
- Otto GA, Puglisi JD (2004) *Cell* 119:369–380.
- Bert AG, Grepin R, Vadas MA, Goodall GJ (2006) *RNA* 12:1074–1083.
- Van der Velden AW, Thomas AA (1999) *Int J Biochem Cell Biol* 31:87–106.
- Pilipenko EV, Pestova TV, Kolupaeva VG, Khitrina EV, Poperechnaya AN, Agol VI, Hellen CU (2000) *Genes Dev* 14:2028–2045.
- Kimball SR, Horetsky RL, Ron D, Jefferson LS, Harding HP (2003) *Am J Physiol Cell Physiol* 284:273–284.